Development of asciminib, a novel allosteric inhibitor of BCR-ABL1-Reference-Cited by-同舟云学术

Development of asciminib, a novel allosteric inhibitor of BCR-ABL1

Published:2022-03 Issue: Volume:171 Page:103580
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Réa Delphine,Hughes Timothy P.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference101 articles.

1. The “hit hard and hit early” approach to the treatment of chronic myeloid leukemia: implications of the updated National Comprehensive Cancer network clinical practice guidelines for routine practice;Akard;Clin. Adv. Hematol. Oncol.,2013

2. BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia;Antelope;Exp. Hematol.,2019

3. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia;Apperley;Lancet Oncol.,2007

4. Kinase-targeted cancer therapies: progress, challenges and future directions;Bhullar;Mol. Cancer,2018

5. What happens to intolerant, relapsed or refractory chronic myeloid leukemia patients without access to clinical trials?;Bosi;Hematol Transfus Cell Ther.,2019

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Outcomes of chronic myeloid leukemia patients after therapeutic failure to conventional tyrosine kinase inhibitors and asciminib;Annals of Hematology;2024-09-13

2. Enzyme Is the Name—Adapter Is the Game;Cells;2024-07-25

3. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib;Leukemia;2024-06-15

4. Repurposing pexmetinib as an inhibitor of TKI-resistant BCR::ABL1;Leukemia;2024-05-15

5. Real-world outcomes in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or chronic myeloid leukemia treated with ponatinib – Final 6-year results from a Belgian registry;2024-03-21